Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Type 2 DiabetesHypertension
Interventions
DRUG

amlodipine, hydralazine, terazosin or hydrochlorothiazide

In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.

Trial Locations (1)

70112

Tulane University Health Sciences Center, New Orleans

All Listed Sponsors
lead

Tulane University School of Medicine

OTHER

NCT02046395 - Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter